Try our Advanced Search for more refined results
Life Sciences - June, 2018
327 articles
- Merck Fosamax Appeal Faces Uncertain Odds In High Court
- Justice Kennedy Leaves Mixed Record On Civil Rights
- Drug, Device Cos. Give $8.4B To Docs, Hospitals In 2017
- 2 Firms Seize Spotlight During Sizzling June For IPOs
- CVC Fund Inks €3.03B Deal For Majority Stake In Recordati
- Drug Wholesaler Alleges Pay-For-Delay Scheme By Novartis
- Chancery Fast-Tracks Drug Trial Investor's Fraud Suit
- Split PTAB Panel Agrees To Review Bovine Breeding Patent
- Trump Says He Will Announce Supreme Court Nominee July 9
- Health Hires: Fenwick, Dechert, Holland & Hart, Carlton Fields
- Kennedy's Retirement: Legacy, Fallout & The Battle Ahead
- Pfizer Draws FDA Rebuke Over Estrogen Ring Video
- Actavis Reaches Tentative Deal To Exit Testosterone MDL
- AbbVie, Besins Owe $448M In FTC Androgel Antitrust Case
- Limiting Law Firms' Professional Liability Risks: Part 3
- Dechert Nabs Simpson Thacher IP, Life Sciences Partner
- New Stats On Millennial Attorney Disciplinary Actions
- J&J, Talc Supplier Can't Escape $117M Verdicts In NJ
- A Midyear Review Of State Attorney General Enforcement
- A Cloud On The Horizon: Trade Secret Theft In The Cloud
- Why The Defense Bar Celebrates Kennedy
- UK Watchdog Looks To Revive £89M Drug Pricing Fine
- Roberts Becomes True Power As 'Kennedy Court' Ends
- 'Opioid Babies' Won't Get Own Track In MDL
- $75M Orexigen Asset Sale Gets Approval In Del. Ch. 11
- PE-Backed BJ's Wholesale Club Leads 7 IPOs Totaling $1.7B
- EEOC Says Firing Over Methadone Treatment Flouted ADA
- What High Court Review Of Fosamax Means For Preemption
- Limiting Law Firms' Professional Liability Risks: Part 2
- Fed. Circ. Backs AstraZeneca, Impax Win In Zomig Patent Suit
- Latham, Goodwin Procter Lead $1.3B Biopharma Merger
- Delay On Kennedy Replacement 'Ain't Going To Happen': GOP
- DaVita Hit With $375M Punitive Damages In Colo. Verdict
- Sessions, HHS Unveil $2B Health Care Fraud Takedown
- From Lawmaker To Lawyer: Prioritizing Is Always Key
- Supreme Court Agrees To Review Fosamax MDL Revival
- From Iqbal To Citizens United: Kennedy's Biggest Decisions
- Life After Kennedy: 1 Big Question, 6 Judges To Watch
- Insider Trading Suspect's Son Shouldn't Testify, Judge Says
- 'Goodbye, Tony!' Justices Bid Farewell To Kennedy
- GSK Planned Off-Label Pitch At Every OB-GYN, Families Say
- When Partisan Passion Raged, Kennedy Was The Vote To Get
- Bio-Rad's IP Suit Over DNA Tech Survives Early Win Bids
- Jefferies Seeks Toss Of Failed Biotech Co. Investors' Suit
- Chinese Used-Car Platform Leads 4 IPOs Raising $394M
- DEA Must Release More Distribution Data In Opioid MDL
- Walmart, Glencore Questioned By NY About Pregnancy Bias
- Mylan Urges Full Fed. Circ. To Ax Vanda Drug IP Under Mayo
- Limiting Law Firms' Professional Liability Risks: Part 1
- GOP Kicks Off Race To Confirm Kennedy Replacement
- From Lawmaker To Lawyer: How Congress Affected My Career
- Research Org. Must Pay $3M For Not Filling Up Clinical Trial
- Justice Kennedy's Retirement To Upset High Court Balance
- Theranos Founder's Stay Bid Nixed As Judge Scolds Counsel
- Natera Loses Bid To Toss Illumina DNA Patent Under Mayo
- 7th Circ. Revives Bid To Warn Court Of 'Objector Blackmail'
- DOJ Sets Aside $110M For Native American Crime Victims
- Accountant Hid Silicon Valley VC Firm's $18M Theft, Jury Told
- Pharma, DEA Push To Keep Opioid MDL Data Under Wraps
- Regeneron Told To Pay Merus Atty Fees In Mice Patent Row
- PTAB To Review Columbia DNA Patent, Let School Defend It
- 3rd Circ. Urged To Revive $1M Tax Penalty Case Against CEO
- Deals Rumor Mill: KKR, ConAgra, Spectrum Pharmaceuticals
- Aurobindo Infringing Bladder Drug Patent, Astellas Says
- 4 Opioid Suit Coverage Rulings Attorneys Should Know
- From Lawmaker To Lawyer: DC Isn't As Bad As You Think
- Supreme Court Decision Weakens Deference To Foreign Laws
- Blockchain Technology Can Help Fight Counterfeit Drugs
- Ex-Akebia Statistician Jailed For Speaking To Trial Witness
- Supreme Court Could Clear Up On-Sale Bar In Patent Cases
- Chinese Online Car Marketplace, Biotechs File 6 IPOs
- FDA Clears First Marijuana-Derived Drug
- Express Scripts Limiting Pharmacy Services Market, Suit Says
- Migraine Supplement Co. Denied Fees After Beating IP Suit
- Justices To Weigh Sexual Energy False Ad Class Cert.
- From Lawmaker To Lawyer: 6 Things I Learned In Congress
- High Court To Hear Patent Case Over On-Sale Bar
- Eli Lilly Beats Dr. Reddy's In Cancer Drug Patent Suit
- House Passes Sweeping Opioid Treatment, Medicare Bill
- Feds Can Use 'Material, Nonpublic Info' At Insider Trading Trial
- PTAB Finds Pain Treatment Patent Invalid In PGR
- 14 Firms To Steer IPOs Surpassing $2.5B To Close Busy June
- Health Care Cos. Raise $228M To Cap 10-IPO Week
- Taxation With Representation: Latham, Davis Polk, Stikeman
- FTC, Memory-Booster Co. Spar Over Errors At 2nd. Circ.
- Native American Cases To Watch In The 2nd Half Of 2018
- Celgene Goes After Synthon's Skin Cancer Drug Generic
- Cheers To 80 Years Of The Food, Drug, And Cosmetic Act
- Jones Day Scores IP Tech Pro From McDermott In Chicago
- Drug Patent Challenges At PTAB By The Numbers
- Smith & Nephew Wants Hip MDL Slashed Over Time Bar
- 1st Circ. Upholds Discovery Bid Nix In Gene-Editing IP Row
- FDA Nixes Biosimilar Guidance Over Burden Concerns
- FDA Clarifies Communication Rules For Medical Product Cos.
- Biggest Native American Rulings Of 2018: Midyear Report
- DLA Piper Adds Ex-Morgan Lewis Partner In NJ
- BigLaw's Associate Salary Model Is A Relic Of A Bygone Era
- Plaintiffs' Firm Pulled Into Cahill Asbestos Suit Discovery War
- Sanofi Judge Skeptical She Was Wrong To Toss Antitrust Suit
- Ex-Masimo VP's 11th-Hour IP Arbitration Bid Earns Eye Roll
- Apology For 'Overheated Rhetoric' Can't Revive Patent Suit
- PTAB's Doors Would Be Closed To Generics Under Hatch Bill
- House Passes Bills On Opioid Patient Info Sharing, Treatment
- Ex-Biopharma Exec Gets 2 Years For Admitting Insider Trades
- Feds Fight Convicted Ex-Valeant Exec's Claims Of Juror Bias
- PTAB Holds Its Grounds In Post-SAS Tyvaso Review
- Allergan Denies Delaying Restasis Generic In Bid To Stop MDL
- Bard Can't Get New Trial After $3.6M Vein Filter Verdict
- BakerHostetler Nabs Brown Rudnick Corporate Partner In OC
- Mintz Levin Adds Ex-MoFo Corporate Partner In San Diego
- Bleichmar Fonti To Lead Endo Investors' Par Pharma Suit
- Tips For Keeping FDA Advisory Action Letters Out Of Court
- Life Sciences Cos. Should Assess Charitable Donations Programs
- Purdue Pharma Axes Sales Team, Lightens Focus On Opioids
- Policy Is Changing For Technology Transfers
- 10 Steps To Modernizing Corporate Integrity Agreements
- Former Aegerion Execs Say FDA Approval Negates FCA Case
- Former Akebia, Merrimack Buddies Face Insider Trading Trial
- Dental Startup Beats Big Distributors' False Ad Claims
- Drinker Biddle Adds IP Pro From Kirkland In Chicago
- #MeToo At Law Firms And What We Can Do About It
- FDA Warning Wire: Cancer Treatment Co. Slammed Again
- DOJ To Participate In Opioid MDL Settlement Talks
- AngioDynamics Seeks Biolitec Patents To Satisfy $75M Award
- Opioid Research Rules Tweaked In Bills Passed By House
- Nevro Pushes For Clarity On Expert Testimony At PTAB
- Pa. Panel Says J&J Unit Must Face Out-Of-State Plaintiffs
- High Court's Vitamin C Ruling Leaves Work For Lower Courts
- Cherokee Nation Sues Purdue Pharma Over Opioids In Okla.
- Nutraceutical Co. Must Pay $5.4M Chinese Award, Court Says
- DC Circ. Backs Boehringer In FTC Atty-Client Privilege Row
- Fed. Circ. Gives Dental Co. Shot To Amend Patent Post-Aqua
- Davis Polk Leads Roche In $2.4B Foundation Medicine Buy
- SEC Sues NY Man Over $11.5M Microcap Co. Stock Scheme
- Merck Implant Suit Barred By Wrongful Birth Law: 1st Circ.
- Abbott Escapes Ill. Suit Over Defibrillator Battery Life
- A Chat With Holland & Knight CFO Mia Stutzman
- Feds Downplay Testimony From Ex-Katten Atty's Loss Expert
- GCs Tackle Law Firm Culture In Diversity Push
- The Hurdles Facing BigLaw's Minority Women
- The Best Firms For Minority Equity Partners
- Knowledge Lawyers Can Help Firms Stay Ahead Of The Curve
- 4 Takeaways From The FDA's Info-Sharing Guidance
- PTAB Rejects Samsung Challenge To Herceptin Patent
- PE-Backed BJ's Leads 9 IPO Launches Exceeding $1.9B
- Dr. Oz Reaches $5M Settlement Over 'Miracle' Diet Pills
- In Their Own Words: Minority Partners On Reaching The Top
- Bayer Dodges Yaz, Yasmin Suit After Improper Expert Report
- CITIC Eyes $3.65B Takeover Of US-Listed China Biologic
- Ferring Will Face Counterclaims In $165M Patent Deal Row
- Lindquist Fights Nix Of Arbitration In Laser-Tech Advice Row
- Bristol-Myers Squibb: 1 Year Later
- The 2018 Law360 Diversity Snapshot
- Insights From State AG Coordinated Opioid Investigation
- Minority Lawyers On Why They Left BigLaw
- Law360's Diversity Snapshot: By The Numbers
- The Best Firms For Minority Attorneys
- Taking On The 'Petri Dish' Of BigLaw Bias
- Law360's Pro Say: What BigLaw Should Do About Diversity
- FCA Decision Tracker: Continued Interpretations Of Escobar
- Hi-Tech Deserves $40M Sanctions, FTC Tells 11th Circ.
- Walgreens' Dual Role Helped Spur Ky. Opioid Crisis, AG Says
- PTAB Takes On Rituxan Patent, Won't Expand Follow-On Rule
- Trump Throws A Curve With Two-Pronged Tariff Approach
- 10 Firms To Steer Biotech-Heavy IPO Lineup Exceeding $1B
- Boston Scientific Wins 3rd Pelvic Mesh Verdict In Mass.
- PE-Backed Avalara Leads 3 IPOs Raising $377M Total
- Attys Reflect On Escobar's FCA Impact 2 Years Later
- Theranos Founder, Ex-COO Indicted For Fraud
- An Unprecedented Look Inside The FARA Unit
- GI Partners Nabs 2 Cos. To Form Human Tissue Storage Biz
- House OKs Tougher Rules For Illegal Drug Analogues
- Health Hires: Honigman, Arnold & Porter, GrayRobinson
- DEA Hemp Rule Is Safe For Now, But That May Change
- Options For Failing Marijuana Cos. And Their Creditors
- Trump Wallops China With Tariffs As IP Brawl Boils Over
- Drugmakers Must Face FTC's AndroGel Antitrust Suit
- USPTO Memo Cuts Mayo Woes On Treatment Method Patents
- Plaintiffs Want AbbVie Fined $500K In Testosterone Row
- Australian Device Co. Inks New Deal To Be Bought For $1.4B
- Aggrenox Buyers Slam Insurers' Bid To Opt Health Plans Out
- Ex-Pitcher Strikes Out On 3rd Swing At MLB Defamation Suit
- Texas Creates MDL For Counties' Opioid Suits
- A Farxiga Opinion That's All Hat, No Cattle
- J&J Talc Customer Paid For Risky Product, 3rd Circ. Told
- New Bill Would Bar Quick Generics Approval For PTAB Users
- Cures Revolution May Reshape Pharmaceutical Landscape
- McKesson Tries To Keep Tribal Opioid Suit In Federal Court
- Why Lawyers Shouldn't Accept Fees In Cryptocurrency: Part 2
- AbbVie Wins 5th Bellwether In Testosterone MDL
- Supreme Court Says Foreign Gov't Submissions Not Binding
- J&J Gets $70M Punitives Slashed In Surgical Stapler Case
- 3rd Circ. Upholds Walgreens Victory In Doc's Defamation Case
- DEA, Media Poised For Battle Over Opioid MDL Data Access
- PTAB Shuts Down Challenge To Gilead's Hep C Drug Patents
- Ex-NJ Lab Prez, Brother Get Prison In $100M Bribery Scheme
- Muscular Dystrophy Drug Co. Seeks To Stall Derivative Suit
- Nutraceutical Appeals Enviros' Fees In Suit It Calls Moot
- 5th Circ. Rejects Pill Mill Doc's Challenge To 5-Year Sentence
- Travelers, Becton Strike Settlement In $167M Coverage Row
- Biotech Co. Pens $18.5M Deal In Investor Fraud Class Action
- California Stuck With Order Barring Glyphosate Warning
- Insys Can't Duck Investor Suit Over Opioid Spray's Financials
- Why Lawyers Shouldn't Accept Fees In Cryptocurrency: Part 1
- J&J Secretly Funded Talc Study, Atty Claims
- 4th Circ. Upholds Ax Of Expert Testimony In Lipitor MDL
- NIH Unveils Research Plans To Fight Opioid Crisis
- Del. Justices Uphold $56M Award In Drug Contract Dispute
- Humana Ordered To Turn Over Docs In EpiPen Antitrust MDL
- Consultant In SEC's Illicit Stock Sale Suit Nabs Early Deal
- House Passes Policy Tweaks Targeting Opioid Abuse
- Drugmakers Denied Patient Info In Opioid MDL Bellwethers
- LabCorp Didn't Make 'Whistleblower' Break Law: Calif. Panel
- Antitrust Chief Defends Sticking To Consumer Welfare Focus
- Allergan's Fat-Freezing Unit Freed From False Ad Claims
- Pharma CEO Cops To $2M Drug Investment Fraud
- FDA Unveils Guidance On Sharing Info On Unapproved Uses
- Pet Pharma Co. Sidesteps Investor Suit Over Dog Drug Delays
- Zimmer NexGen MDL Nears Finish With Confidential Deal
- Attys Want $47M From $166M Lidoderm Pay-For-Delay Deal
- Clearer Rule On Witness Compensation Disclosure Is Needed
- Wilson Sonsini Nabs Squire Patton Tech, Life Sci Pro In LA
- Ex-Insys Execs Can't Get More Info On Charges, Feds Say
- FDA Risk-Evaluation Guidance Unlikely To Help Generics
- Alta Partners Rakes In $130M For Health Care-Focused Fund
- PTAB Invalidates Most Of Pfizer Pneumonia Vaccine Patent
- Fed. Circ. Denies Atty Fees In Kidney Device Patent Case
- Drug Cos. Unleash Opioid MDL Counterattacks
- Justices Won't Hear Cleveland Clinic Patent Eligibility Case
- Deals Rumor Mill: TPG, Stryker, Fortum
- Aggrenox MDL Nears End As Drug Cos. Reach Final Deal
- Lawmakers Seek To Hold USPS 'Accountable' In Opioid Bill
- Fed. Circ. Revives Medtronic Bid To Ax Patent In $23.5M Row
- Justices Won't Weigh Rest Break Pay, Pfizer Unit Bias Suit
- Eagle Wins Orphan Drug Status In Row With FDA
- Merck Urges Justices To Review Fosamax MDL Revival
- Mistrial Called In J&J Talc Trial After Cancer Victim Dies
- Panel Centralizes Zetia Antitrust MDL In Va.
- Ariosa Fights Sales Ban, Says It's Not An Illumina Competitor
- Plavix MDL Judge Tosses 95 Cases Due To Inaction
- Brand Battles: A 'Triple Crown' Trademark Fight
- Meet The Lobbyist Battling FDA In Epic Supplement Clash
- Par Infringed Colonoscopy Drug Patents, Fed. Circ. Affirms
- Impediments To Legal Industry's 'Inevitable' Future: Part 2
- 6 Firms To Steer 7 IPOs Exceeding $1.4B As June Gets Hot
- Philly Xarelto Patients Fight Bellwether-Manipulation Claim
- Roche, Humana Can't Flee FCA Suit Over Debt Deal
- Tennis Player Wants $10M Injury Suit Back In State Court
- Ironshore, 23andMe Get ADR OK In DNA Case Coverage Row
- PTAB Nixes Patent For Valeant's Antifungal Jublia
- Shareholder Suits Over Calif. Co.'s Roche Deal Consolidated
- Blocking Patent Focus Of Acorda's Fed. Circ. MS Drug Appeal
- FTC Says Patent Infringement Suits Are Not Antitrust Proof
- UK Tribunal Overturns £89M Epilepsy Drug Pricing Fine
- Biogen, Drugmaker Settle Angiomax Patent Royalties Row
- Schlichtmann Must Face Avandia Settlement Malpractice Row
- Impediments To Legal Industry's 'Inevitable' Future: Part 1
- Drug Co. Lundbeck To Settle Charity Support Probe For $52M
- Walgreen, Kroger Join J&J's Remicade Antitrust Brawl
- Latest J&J Talc Trial Pits Co. Against 22 Women
- SEC Says BioChemics Is Unable To Pay $17M Bill To Investors
- Convicted Valeant Exec Says Dishonest Juror Tainted Trial
- Reseller Not Enough To Keep Medical Device IP Row In Texas
- Deals Rumor Mill: PetSmart, Azelis, BHP
- Fortive Offers $2.7B To Acquire J&J Medical Products Unit
- Alston Picks Up Ex-Drinker Biddle Product Liability Partner
- King & Spalding Nabs International Arbitration Pro In Paris
- Genentech Wants White & Case To Share Samsung Drug Info
- Calif. Court Affirms State Rule For Lead Discharge Levels
- Fosamax Users Urge High Court To Turn Down Merck Appeal
- LabCorp Slams Claims It Conspired To Block Del. Startup
- J&J Battles To Throw Out $117M Verdicts In NJ Talc Case
- Supplement Maker Can't Prove Consent Judgment Violated
- Gov't Keeps FCA Claims Against Sleep-Testing Co. Alive
- FCPA Enforcement Activity In Early 2018: Part 2
- 7 Common Mistakes In Company Witness Prep
- Pfizer's Investment Arm Snags $600M With Eye On Biotechs
- AbbVie Wore 'Blinders' On AndroGel's Clot Risk, Jury Told
- Hard Hit By Opioids, Tribes To Get Own Track Within MDL
- VC-Backed Verrica Pharmaceuticals Joins June IPO Parade
- Don't Revive Opioid Patents, Generics Maker Tells Fed. Circ.
- 3rd Circ. Revives Suit Of Nurse Fired After Vaccine Refusal
- Viveve, Thermi Settle Suit Over Vagina Reshaping Patent
- FDA Warning Wire: Online Opioid Sales, Caffeine Crackdown
- SEC Probe Into Biotech Co. Made Shares Drop, Investor Says
- Deals Rumor Mill: Abu Dhabi National Oil, Recordati, Abraaj
- Zydus Defends Antitrust Claims In Prevacid Patent Suit
- Dynavax Hepatitis Vaccine Shareholder Suit Tossed Again
- FCPA Enforcement Activity In Early 2018: Part 1
- Class Counsel To Collect Over $6M In Akorn Accounting Row
- Moving Toward A Standard Of Care For Medical Marijuana
- Deal OK Sought In OvaScience Director Compensation Suit
- How New Testimonial Evidence Affects IPR Institution
- Investors Denied Default $11.1M Award In Tibet Pharma Suit
- Filmmaker Takes 2nd Crack At Theranos Deposition Footage
- Humana, Drug Cos. Settle In Aggrenox Pay-For-Delay Row
- Fed. Circ. Weighs Immunity From IPR In Tribal IP Transfer
- Express Scripts, CVS Want EpiPen Cost ERISA Suit Tossed
- FDA Says 5 More Deaths Tied To Obesity Stomach Balloons
- PTAB Interpreting SAS Too Broadly, Knee Implant Co. Says
- End-Payor Attys Want $16M From $43M Medicis, Impax Deals
- Pfizer Unit Used Partnership To Cut Rival's Supply, Suit Says
- Regeneron Urges Justices To Ax Inequitable Conduct Ruling
- Medicaid Groups' Atty Seeks Spot On Opioid Exec Committee
- Atty's 17 Years For Stock Scheme Was Proper, Feds Say
- Fenwick & West Nabs Technology Exec Compensation Partner
- Clinic Says Patent Eligibility 'Begs' For High Court Help
- Fed. Circ. Weighs In On Obviousness-Type Double Patenting
- Allergy Tester Wants Baker Donelson DQ'd From Antitrust Suit
- FDA Drug Review Office Plans Overhaul To Boost Efficiency
- 7th Circ. Says Expert Necessary To Sue Teva Over Broken IUD
- Why Widespread Use Of Live Video Testimony Is Not Justified
- Tech 'Unicorn' Domo Among 6 Cos. Filing IPO Plans
- Drinker Biddle Adds Ex-Dentons Trade Secrets Leader
- Momenta, Sandoz Denied Mid-Suit Antitrust Claims Appeal
- Charity Sues Insurer To Cover Calif. DOJ's False Ad Suit
- Shkreli Deals Saved Retrophin Millions, Ex-Katten Atty Argues
- Tribal Immunity At The Fed. Circ.: What You Need To Know
- Cooley Nabs Katten Litigator For Securities Practice
- HHS To Delay Drug Pricing Rule To July 2019
- Theranos Indirect Investors Denied Class Cert. For Fraud Suit
- Merck Shareholder's Doc Request Too Broad, NJ Court Says
- A Peek Into The World Of NAD Director Laura Brett
- Seneca Nation Says Pharma Cos. At Fault For Opioid Crisis
- Judging A Book: Wallach Reviews 'Uncivil Warriors'
- Health Hires: K&L Gates, Womble Bond, Bellicum Pharma
- A Closer Look At New Federal 'Right To Try' Law